The growth hormone axis had an unusually busy twelve months in the peer-reviewed literature — but almost none of it came from the compounds most discussed in research-peptide circles. The new data came from two approved ghrelin-receptor drugs, an orally active secretagogue that re-entered Phase 3 this spring, a meta-analysis of the one approved GHRH analog, and a wave of mainstream clinical reviews that, for the first time, name the gray-market catalog compound by compound.
That gap is itself the story. Here is what actually landed, with sources and dates.
The ghrelin receptor got its close-up — and both ligands were approved drugs
The most mechanistically substantial paper of the period is structural. Writing in Acta Pharmacologica Sinica (November 2025), a group reported high-resolution cryo-electron microscopy structures of the growth hormone secretagogue receptor (GHSR/GHS-R1a) bound to two clinically approved agonists in complex with Gq protein — macimorelin at 2.63 Å and anamorelin at 2.52 Å.
Both ligands occupied a bifurcated binding pocket split by a conserved salt bridge between E124(3.33) and R283(6.55). Mutagenesis identified the residues underlying anamorelin's higher binding affinity relative to macimorelin. The authors also compared GHSR bound to different G protein subtypes, resolving the structural basis for coupling selectivity.
That last point is the one worth carrying forward. Every ghrelin-mimetic in the catalog — ipamorelin, GHRP-2, GHRP-6, hexarelin — acts at this same receptor. Same receptor does not mean same output. The differences described in the research literature for these peptides are largely about downstream hormonal specificity (whether GH release comes with cortisol, ACTH, or prolactin spillover) rather than receptor-subtype selectivity, and the structural work gives a physical vocabulary for why two agonists at one receptor need not behave identically.
Macimorelin also generated clinical data. In Pituitary (March 7, 2026), a single-center retrospective study of 37 adults examined real-world performance of the macimorelin stimulation test for adult GH deficiency. The FDA-approved GH cut-off of 2.8 ng/mL classified 40.5% of patients as deficient; a post hoc proposed cut-off of 5.1 ng/mL classified 54.0% — an absolute yield difference of 13.5%. Discordant classifications clustered in patients with higher BMI (37.7 vs 28.2 kg/m² on average), consistent with the long-established observation that adiposity blunts GH response to provocation. Omitting the 90-minute sample did not change any diagnostic call in this cohort.
Two takeaways: the only GHS-R agonist approved in the US and EU is a diagnostic, not a therapy — and even in that narrow use, body composition moves the readout.
Anamorelin's real-world year: cachexia reversal, and a glucose signal
Anamorelin is a GHS-R agonist approved only in Japan, for cancer cachexia. Its 2026 literature is unusually informative because it is the closest thing to a long-running human experiment in sustained ghrelin-receptor agonism.
SPIRAL-ANA (Journal of Cachexia, Sarcopenia and Muscle, 2026) was a prospective multicentre observational study across 29 Japanese institutions: 123 patients with advanced NSCLC and cachexia enrolled, 114 in the full analysis set, median age 73. Objective response rate was 57.9%; median PFS 6.2 months and median OS 18.5 months. The primary endpoint was not met — the lower bound of the PFS confidence interval did not exceed the predefined 5-month threshold.
The secondary findings are more interesting than the miss. At week 12, 71.8% of evaluable patients had transitioned out of cachexia, and a landmark analysis showed those patients lived substantially longer than those who remained cachectic (19.9 vs 7.1 months; HR 2.19, 95% CI 1.19–4.02). The authors frame cachexia reversal as a possible surrogate for survival benefit — a hypothesis generated by the study, not proven by it.
On safety, SPIRAL-ANA reported grade ≥3 hyperglycemia in 5.1%. A separate single-center retrospective study in Anticancer Research (May 2026) found much higher numbers: among 129 patients, hyperglycemia in 29.5%, grade ≥3 in 20.2%, with 81.6% of events inside the first 28 days. Diabetes mellitus and ALT >42 IU/L were independent predictors.
The gap is not evidence of under-reporting in trials. It is population and definition: that cohort was 38% pancreatic cancer, used a >200 mg/dL glucose threshold, and ran alongside chemotherapy co-medications. What generalizes is the mechanism — GHS-R agonism raises GH, and GH drives insulin resistance. That is a class-level property of the GH secretagogue axis. Applying anamorelin's numbers to GHRP-2 or hexarelin would be an inference, not a measurement.
One more paper deserves a careful read rather than a citation. A propensity-matched retrospective study in European Journal of Clinical Pharmacology (June 2026) reported improved serum creatinine and eGFR with anamorelin and called the effect possibly renoprotective. Creatinine is generated by muscle. A drug whose purpose is reversing muscle wasting changes creatinine production, which moves creatinine-based eGFR without any change in glomerular filtration. The abstract reports BUN, creatinine, and eGFR — no cystatin C — so that confound is unaddressed. This is a good example of a real finding whose interpretation is not settled.
An oral secretagogue re-entered Phase 3
LUM-201 (Lumos Pharma) is an orally administered small molecule — ibutamoren, from the MK-0677 lineage — not a peptide. It is a potent GHS-R agonist described as increasing the amplitude of endogenous pulsatile GH secretion rather than replacing the hormone.
Phase 2 OraGrowtH210/212 data in moderate pediatric GH deficiency reported annualized height velocity of 8.2 cm/yr at six months and 8.0 cm/yr at twelve months on the 1.6 mg/kg oral arm, within the prespecified margin of the injectable recombinant GH comparator — reportedly achieved at roughly 20% of the GH concentration seen with injectable rhGH. The Phase 3 OraGrowtH trial (NCT06948214) is a 12-month randomized, double-blind, placebo-controlled study, estimated enrollment 150, which began enrolling May 20, 2026 and is currently recruiting. It uses a predictive enrichment marker to select likely responders.
Note why the oral route works here: LUM-201 is a small molecule, not a peptide. Orally dosed peptides are digested and poorly absorbed, which is the structural reason nearly every catalog secretagogue is studied by injection in the published literature — see our pharmacokinetics primer.
Tesamorelin: a meta-analysis, and a null cognition pilot
Tesamorelin remains the only approved GHRH analog and the best-characterized member of the class.
A meta-analysis of five randomized controlled trials in Obesity Research & Clinical Practice (January–February 2026) pooled tesamorelin versus placebo in HIV-associated lipodystrophy through July 2025. Results: visceral adipose tissue −27.71 cm², trunk fat −1.18 kg, limb fat −0.22 kg, hepatic fat −4.28 percentage points, waist circumference −1.61 cm, and lean body mass +1.42 kg — with no significant change in subcutaneous adipose tissue or BMI, and no significant change in CD4+ T-cell counts. Reported adverse events were arthralgia, myalgia, paresthesia, and injection-site erythema.
Read the endpoint list carefully: these are surrogate measures — compartment fat, hepatic fat fraction, lean mass — not clinical events. There is no cardiovascular outcomes trial in this evidence base.
Two more tesamorelin items. A double-blind placebo-controlled pilot in eNeurologicalSci (2026) treated 22 adults with cognition ranging from normal to mild cognitive impairment for 10 weeks (NCT02553603) and found no significant treatment-related change in body composition, fatigue, sleep, physical performance, glucose tolerance, cognition, or brain morphometry. Exploratory machine-learning analysis flagged possible differences in two brain regions; that is a post hoc hypothesis, not a result. And a protocol paper in BMJ Open (July 8, 2026) describes TRIUMPH (NCT06554717), a two-site randomized trial of tesamorelin plus a home-based exercise program in 100 older adults living with HIV. Worth flagging for name collision: this TRIUMPH is unrelated to the retatrutide TRIUMPH program — a reminder that trial acronyms are reused freely, as covered in our nomenclature primer.
The bigger 2026 development: mainstream reviews named the shelf
The most consequential shift is bibliographic. Through 2026, at least six peer-reviewed clinical reviews addressed research-market GH-axis peptides by name rather than as an undifferentiated category.
A narrative review in Frontiers in Endocrinology (2026) is the clearest of these. It explicitly covers GHRH analogs (sermorelin, tesamorelin, CJC-1295 with DAC and without DAC), secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), the GH fragment AOD-9604 / hGH 176-191, and IGF-1 analogs (PEG-MGF, IGF-1 LR3). Its method is to stratify these compounds into evidence tiers, from regulatory-grade randomized trial data down to a complete absence of human studies, and to contrast that evidence with circulating self-administration protocols. It catalogs reported adverse effects across endocrine and metabolic disturbance, fluid retention, myalgia/arthralgia, and injection-site reactions, and it names uncertainty about product composition in unregulated supply chains as a distinct interpretive problem.
Parallel reviews appeared in Sports Medicine (April 2026), JBJS Reviews (May 2026), American Journal of Sports Medicine (January 2026), JAAOS Global Research & Reviews (January 2026), and Journal of Sports Medicine and Physical Fitness (July 2026). Their shared conclusion: preclinical results are frequently favorable, rigorous human safety data are scarce, and regulatory status varies enormously within what buyers treat as one category. On the analytical side, Journal of Pharmaceutical and Biomedical Analysis (January 15, 2026) published a nano-LC–Orbitrap method for detecting GHRH and its analogs in urine — the anti-doping laboratory catching up to the market.
For a researcher, the practical value is straightforward: these reviews are free, citable, neutral tier-maps of exactly the compounds on the shelf. They are a better starting point than any vendor description. Our own structural map of the same class is in the growth hormone peptide class primer.
Frequently asked questions
Does the cryo-EM work say anything about which GHRP is "better"? No. It resolves how two approved drugs — macimorelin and anamorelin — engage GHS-R1a and how the receptor couples to different G proteins. It did not include ipamorelin, GHRP-2, GHRP-6, or hexarelin. It supports the general principle that agonists at one receptor can produce different signaling output; it does not rank the catalog.
Why does an approved GHRH analog have meta-analysis data while catalog secretagogues do not? Because tesamorelin completed a registrational program with defined endpoints and published trials. Most research-market secretagogues have never been through comparable human study, which is precisely the gradient the 2026 review wave was written to describe. Evidence maturity, not mechanism, is the dividing line.
Are the anamorelin hyperglycemia numbers relevant to other secretagogues? Mechanistically the concern is class-level — GH secretion raises insulin resistance. But those specific incidence figures come from cancer patients on chemotherapy with a defined glucose threshold, and cannot be transferred to another compound or another population as a measurement.
Independent verification of what is in a vial remains a separate question from what the literature says about a molecule — see our quality standards and the full compound library.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.